Table 3.
Number of HCC patients at different stages identified by serum SELDI-TOF-MS pattern and AFP20
Tumor stage | Number of patients | SELDI-TOF-MS pattern (n/%) | AFP20 (n/%) |
---|---|---|---|
I | 46 | 40/87% | 25/54%* |
II | 36 | 32/89% | 26/72% |
III | 38 | 37/97% | 32/84% |
Total | 120 | 109/91% | 83/69% |
Note: AFP20, at a cutoff value >20 ng/mL
* Compared with SELDI-TOF-MS, P < .05